StreetInsider.com News Articles

Form 6-K MOLECULAR PARTNERS AG For: Jul 06

Tue, 07 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26737769.html

Form 6-K MOLECULAR PARTNERS AG For: Jul 06

Tue, 07 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26737769.html

Form 6-K MOLECULAR PARTNERS AG For: Jul 06

Tue, 07 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26737769.html

H.C. Wainwright Reiterates Buy Rating on Molecular Partners (MOLN)

Mon, 06 Jul 2026 06:36:46 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $13.00 price target on Molecular Partners (NASDAQ: MOLN).

The analyst commented: "Late last week, Molecular Partners and its partner, Orano Med (private), announced that it has dosed the first patients in a U.S.-based, multicenter Phase 1/2a trial evaluating MP0712, a DLL3-targeted 212Pb-armed Radio-DARPin, as 2L+ therapy for patients with locally advanced/metastatic SCLC and other DLL3-expressing neuroendocrine tumors; initial results (mainly safety) from this trial are expected later this year, with a more complete dataset (including efficacy) anticipated in 1H27 (potentially at ASCO 2027). We remind investors of the previously released imaging

Form 6-K MOLECULAR PARTNERS AG For: Jul 02

Thu, 02 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26723587.html

Form 6-K MOLECULAR PARTNERS AG For: Jul 02

Thu, 02 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26723587.html

Form 6-K MOLECULAR PARTNERS AG For: Jul 02

Thu, 02 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26723587.html

Form S-8 MOLECULAR PARTNERS AG

Wed, 24 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260624/26685563.html

Form S-8 MOLECULAR PARTNERS AG

Wed, 24 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260624/26685563.html

Form S-8 MOLECULAR PARTNERS AG

Wed, 24 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260624/26685563.html

Form 6-K MOLECULAR PARTNERS AG For: May 30

Mon, 01 Jun 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260601/26579124.html

Form 6-K MOLECULAR PARTNERS AG For: May 30

Mon, 01 Jun 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260601/26579124.html

Form 6-K MOLECULAR PARTNERS AG For: May 30

Mon, 01 Jun 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260601/26579124.html

Molecular Partners AG (MOLN) Misses Q1 EPS by 28c

Tue, 12 May 2026 17:46:11 -0400

Molecular Partners AG (NASDAQ: MOLN) reported Q1 EPS of ($0.67), $0.28 worse than the analyst estimate of ($0.39).

For earnings history and earnings-related data on Molecular Partners AG (MOLN) click here.

Form 6-K MOLECULAR PARTNERS AG For: Mar 31

Tue, 12 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260512/26477441.html

Form 6-K MOLECULAR PARTNERS AG For: Mar 31

Tue, 12 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260512/26477441.html

Form 6-K MOLECULAR PARTNERS AG For: Mar 31

Tue, 12 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260512/26477441.html

Form 6-K MOLECULAR PARTNERS AG For: May 01

Fri, 01 May 2026 09:22:00 -0400

si-local-file:///var/storage/secattach/20260501/26413094.html

Form 6-K MOLECULAR PARTNERS AG For: May 01

Fri, 01 May 2026 09:22:00 -0400

si-local-file:///var/storage/secattach/20260501/26413094.html

Form 6-K MOLECULAR PARTNERS AG For: May 01

Fri, 01 May 2026 09:22:00 -0400

si-local-file:///var/storage/secattach/20260501/26413094.html

Molecular Partners publishes phase 1 data showing tumor-targeted therapy

Fri, 01 May 2026 07:00:37 -0400

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) published phase 1 clinical data in Nature Cancer for its experimental cancer drug MP0317, according to a company statement.

The study involved 46 patients with advanced solid tumors and demonstrated that MP0317 activated CD40 pathways specifically within tumors while showing a favorable safety profile. One patient achieved an unconfirmed partial response and 14 patients experienced stable disease.

MP0317 is designed to activate immune cells within the tumor microenvironment by binding to fibroblast activation protein, which is highly expressed in tumor stroma. The drug can be dosed weekly or every three weeks based on its pharmacokinetic

Molecular Partners publishes phase 1 data showing tumor-targeted therapy

Fri, 01 May 2026 07:00:37 -0400

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) published phase 1 clinical data in Nature Cancer for its experimental cancer drug MP0317, according to a company statement.

Molecular Partners publishes phase 1 data showing tumor-targeted therapy

Fri, 01 May 2026 07:00:37 -0400

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) published phase 1 clinical data in Nature Cancer for its experimental cancer drug MP0317, according to a company statement.

Molecular Partners publishes phase 1 data showing tumor-targeted therapy

Fri, 01 May 2026 07:00:37 -0400

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) published phase 1 clinical data in Nature Cancer for its experimental cancer drug MP0317, according to a company statement.

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

Fri, 01 May 2026 07:00:00 -0400

Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer types
Pharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitors
Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”),